Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PARD6B CRISPR/Cas9 KO Plasmid (m): sc-425492
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PARD6B CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PARD6B genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PARD6B Antibody (B-10): sc-166405
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PARD6B CRISPR/Cas9 KO Plasmid (m) | sc-425492 | 20 µg | $397.00 |
Overview
Pard6b encodes PARD6B, a core component of the PAR polarity complex that cooperates with PRKCZ/PRKCI and PARD3 to establish apico-basal polarity and organize epithelial junctions. Through coupling to CDC42 and regulation of the actin cytoskeleton, PARD6B influences tight junction assembly, asymmetric cell division, and directed migration during development and tissue homeostasis. Perturbation of PAR complex signaling is broadly linked to defects in epithelial barrier function and dysregulated morphogenesis, processes frequently altered in models of tumor progression and metastasis. In mouse systems, Pard6b is commonly studied in the context of polarity-dependent signaling, junctional remodeling, and lineage specification.
PARD6B CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Pard6b gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Pard6b together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Pard6b open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PARD6B protein expression.
This CRISPR knockout system enables efficient generation of Pard6b-deficient cell models for investigation of PARD6B signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Pard6b exon(s) critical for PARD6B function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Pard6b genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PARD6B CRISPR/Cas9 KO Plasmid (m) and PARD6B CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Pard6b locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PARD6B HDR Plasmid (m) and PARD6B HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Pard6b homology arms to support homology-directed repair at defined Pard6b target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.